跳至主要内容
临床试验/NCT00633438
NCT00633438已完成4 期

A Double-Blind, Placebo-Controlled, Randomized Comparison Study of the Efficacy of Celebrex 400 mg Single Dose Pre and Celebrex 200 mg Post Ambulatory Arthroscopic Knee Surgery for Total Analgesic Use After Surgery

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 个研究点 分布在 1 个国家目标入组 204 人开始时间: 2004年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
204
试验地点
1
主要终点
Total analgesic use (hydrocodone bitartrate 5 mg/acetaminophen 500 mg [HC/APAP]) after surgery

研究概览

简要总结

To compare total analgesic use at 24 hours after arthroscopic knee surgery in celecoxib-treated versus placebo-treated patients

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion criteria:
  • Diagnosed (or suspected to have) meniscus trauma of the knee requiring ambulatory arthroscopic knee surgery
  • Willing to participate in study for 36 hours and come to follow-up visit 7 days post surgery

排除标准

  • Exclusion criteria:
  • Osteoarthritis, inflammatory arthritis, or previous fracture of index joint
  • Received acetaminophen or low dose narcotic (vicodin/tylox) within 8 hours of surgery
  • Have received oral (4 weeks), intramuscular (2 months), intra-articular (3 months) or soft-tissue (2 months) injections of corticosteroids of the first dose of study medication or intra-artcular injections of hyaluronic acid in the index joint within 9 months of the first dose of study medication

研究组 & 干预措施

B

Placebo Comparator

干预措施: Placebo (Other)

A

Experimental

干预措施: Celecoxib (Drug)

结局指标

主要结局

Total analgesic use (hydrocodone bitartrate 5 mg/acetaminophen 500 mg [HC/APAP]) after surgery

时间窗: 24 hours

次要结局

  • Physical exam(Day 7)
  • Number and percentage of patients taking HC/APAP after surgery(1, 2, 6, 8, 10, 12, 24, 36 hours)
  • Time to analgesic use after surgery(1, 2, 6, 8, 10, 12, 24, 36 hours)
  • Patient Assessment of Pain, according to visual analogue scale, after surgery at rest and flexion(1, 2, 6, 8, 10, 12, 24, 36 hours)
  • Adverse events(Day 7)
  • Vital signs(Day 7)
  • Laboratory evaluation(Day 7)

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验